Direct oral anticoagulants in patients with obesity and atrial fibrillation: position paper of Italian National Association of Hospital Cardiologists (ANMCO)

D Mocini, SA Di Fusco, E Mocini, LM Donini… - Journal of Clinical …, 2021 - mdpi.com
The use of the direct oral anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban
(DOACs) offers some major advantages over warfarin and other vitamin K antagonists …
被引用次数：14 相关文章

Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO).

D Mocini, SA Di Fusco, E Mocini… - Journal of Clinical …, 2021 - search.ebscohost.com
The use of the direct oral anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban
(DOACs) offers some major advantages over warfarin and other vitamin K antagonists …

Direct oral anticoagulants in patients with obesity and atrial fibrillation: Position paper of italian national association of hospital cardiologists (ANMCO)

D Mocini, SA Di Fusco, E Mocini, LM Donini… - JOURNAL OF …, 2021 - iris.uniroma1.it
The use of the direct oral anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban
(DOACs) offers some major advantages over warfarin and other vitamin K antagonists …

Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO).

D Mocini, SA Di Fusco, E Mocini, LM Donini… - Journal of Clinical …, 2021 - europepmc.org
The use of the direct oral anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban
(DOACs) offers some major advantages over warfarin and other vitamin K antagonists …
[HTML] nih.gov

[HTML][HTML] Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO)

D Mocini, SA Di Fusco, E Mocini… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
The use of the direct oral anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban
(DOACs) offers some major advantages over warfarin and other vitamin K antagonists …
[PDF] academia.edu

[PDF][PDF] Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO)

D Mocini, SA Di Fusco, E Mocini, LM Donini, C Lavalle… - J. Clin. Med, 2021 - academia.edu
The use of the direct oral anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban
(DOACs) offers some major advantages over warfarin and other vitamin K antagonists …

Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO)

D Mocini, SA Di Fusco, E Mocini… - Journal of Clinical …, 2021 - search.proquest.com
The use of the direct oral anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban
(DOACs) offers some major advantages over warfarin and other vitamin K antagonists …

Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO)

D Mocini, SA Di Fusco, E Mocini… - Journal of clinical …, 2021 - pubmed.ncbi.nlm.nih.gov
The use of the direct oral anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban
(DOACs) offers some major advantages over warfarin and other vitamin K antagonists …
[PDF] semanticscholar.org

[PDF][PDF] Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO)

D Mocini, SA Di Fusco, E Mocini, LM Donini… - J. Clin …, 2021 - pdfs.semanticscholar.org
The use of the direct oral anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban
(DOACs) offers some major advantages over warfarin and other vitamin K antagonists …